Диссертация (1141158), страница 19
Текст из файла (страница 19)
J Affec Dis. 2001;62:17-31.45. Akiskal H.S. The Prevalent Clinical Spectrum of Bipolar Disorders: BeyondDSM-IV. J Clin Psychopharmacol. 1996;16(2Suppl):4-14.11446. Akiskal H.S., Akiskal K. Re-assessing the prevalence of bipolar disorders:Clinical significance and artistic creativity. Psychiatr Psychobiol. 1988;3:19-36.47. Akiskal H.S., Khani M.K., Scott-Strauss A. Cyclothymic temperamentaldisorders. Psychiatry Clin North Am.
1979;2:527-554.48. Akiskal H.S., Mallya G. Criteria for the "soft" bipolar spectrum: treatmentimplications. Psychopharmacol Bull. 1987;23(1):68-73.49. Akiskal H.S., Maser J.D., Zeller P. et al. Switching from unipolar to bipolar II:an 11-year prospective study of clinical and temperamental predictors in 559patients. Arch Gen Psychiatry.
2003;60:261-269.50. Akiskal H.S., Pinto O. The evolving bipolar spectrum: prototypes I, II, III and IV.Psychiatr Clin North Am. 1999;22:517-53451. Alloy B.L., Uroshevic S., Abramson L.Y. et al. Progression along the bipolarspectrum: a longitudinal study of predictors of conversion from bipolar spectrumconditions to bipolar I and II disorders.
J Abnorm Psychol. 2012;121(1):16-27.52. Altshuler L., Kiriakos L., Calcagno J. et al. The impact of antidepressantsdiscontinuation versus antidepressants continuation on 1-year risk for relapse ofbipolardepression:aretrospectivechartreview.JClinPsychiatry.2001;62(Suppl8):612-616.53. Altshuler L., Suppes T., Black D.O., Nolen W.A., Leverich G., Keck P.E.
Jr. etal. Lower switch rate in depressed patients with bipolar II than bipolar I disordertreated adjunctively with second-generation antidepressants. Am J Psychiatry.2006;163:313-315.54. Altshuler L., Suppes Т., Black D. et al. Impact of antidepressant discontinuationafter acute bipolar depression remission on rates of depressive relapse at 1-yearfollow-up. Am J Psychiatry. 2003;160:1252-1262.55. Altshuler L.L., Post R.M., Leverich G.S., Mikalauskas K., Rosoff A., AckermanL. Antidepressant-induced mania and cycle acceleration: a controversy revisited.Am J Psychiatry. 1995;152(8):1130-1138.11556.
Amsterdam J.D., Shults J. Comparison of short-term venlafaxine versus lithiummonotherapy for bipolar II major depressive episode: a randomized open-labelstudy. J Clin Psychopharmacol. 2008;28(2):171-181.57. Amsterdam J.D., Shults J. Comparison of fluoxetine, olanzapine and combinedfluoxetine plus olanzapine initial therapy of bipolar type I and type II majordepression: lack of manic induction. J Affect Disord. 2005;87(1):121-130.58.
Angst J. Course of affective disorders / In: Handbook of Biological Psychiatry,van Praag (ed.). New York: Marcel Dekker, 1981;225-242.59. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. JAffect Dis. 1998;50(2-3):143-151.60. Angst J., Gamma A., Benazzi F. et al.
Diagnostic issues in bipolar disorder. EurNeuropsychopharm. 2003;13(2):43-50.61. Angst J., Marneros A. Bipolarity from ancient to modern times: conception, birthand rebirth. J Affec Dis. 2001;67:3-19.62. Angst J., Preisig M. Course of a clinical cohort of unipolar, bipolar andschizoaffective patients. Results of a prospective study from 1959 to 1985.Schweiz Arch Neurol Psychiatry. 1995;14a:5-16.63.
Angst J., Sellaro R. Historical perspectives and natural history of bipolardisorder. Biol Psychiatry. 2000;48:445-457.64. Angst J., Sellaro R., Merikangas K.R. Depressive spectrum diagnoses. ComprPsychiatry. 2000;41(2Suppl1):39-47.65. Angst J., Stassen H.H., Clayton P.J.
et al. Mortality of patients with mooddisorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167-181.66. Baldessarini R.J., Tondo L. Harvard Medical School Guide to Assessment andIntervention in Suicide. San Francisco, Calif: Jossey-Bass, 1988. 355 p.67. Baldessarini R.J., Tondo L., Hennen J. Effects of lithium treatment and itsdiscontinuation on suicidal behavior in bipolar manic-depressive disorder. J ClinPsychiatry. 1999;60(Suppl2):77-84.11668. Ballenger J.C., Post R.M. Carbamazepine in manic-depressive illness: a newtreatment.
Am J Psychiatry. 1980;137:782-790.69. Bauer M.S., Calabrese J.R., Dunner D.L. et al. Multisite data reanalysis of thevalidity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. AmJ Psychiatry. 1999;151:506-515.70. Bebbington P., Ramana R. The epidemiology of bipolar affective disorder. SocPsychiatry Psychiatr Epidemiol.
1995;30:279-292.71. Benazzi F. Prevalence of bipolar II disorder in outpatient depression: A 203-casestudy in private practice. J Affect Disord. 1997;43:163-166.72. Benazzi F. Atypical depression in private practice depressed outpatients: a 203case study. Compr Psychiatry. 1999;40(1):80-83.73. Benazzi F. Prevalence of bipolar II disorder in atypical depression. Eur ArchPsychiatry Clin Neurosci. 1999;249(2):62-65.74. Benazzi F. Depression with DSM-IV atypical features: a marker for bipolar IIdisorder. Eur Arch Psychiatry Clin Neurosci.
2000;250:53-55.75. Berk M., Berk L., Moss K., Dodd S., Malhi G.S. Diagnosing bipolar disorder:how can we do it better? Med J Aust. 2006;184(9):459-62.76. Berk M., Dodd S., Callaly P., Berk L., Fitzgerald P., de Castella A.R., Filia S.,Filia K., Tahtalian S., Biffin F., Kelin K., Smith M., Montgomery W., Kulkarni J.History of illness prior to a diagnosis of bipolar disorder or schizoaffectivedisorder.
J Affect Disord. 2007;103(1-3):181-186.77. Bond D.J., Lam R.W., Yatham L.N. Divalproex sodium versus placebo in thetreatment of acute bipolar depression: a systematic review and meta-analysis. JAffect Disord. 2010;124:228–234.78. Bottlender R., Rudolf D., Strauss A., Möller H.J. Antidepressant-associatedmaniform states in acute treatment of patients with bipolar-I depression. Eur ArchPsychiatry Clin Neurosci.
1998;248(6):296-300.79. Bowden C.L. A different depression: clinical distinctions between bipolar andunipolar depression. J Affect Disord. 2005;84(2-3):117-125.11780. Bowden C.L. Lamotrigine in the treatment of bipolar disorder. Expert OpinPharmacother. 2002;3:1513-1519.81.
Bowden C.L. Strategies to reduce misdiagnosis of bipolar depression. PsychiatrServ. 2001;52(1):51-55.82. Calabrese J.R., Macfadden W., McCoy R., Minkwitz M., Wilson E., Kuklen J.Double-blind placebo-controlled study of quetiapine in bipolar depression. АРАAnnual Meeting, New YORK, Abstracts NR, 2004.83. Calabrese J.R., Bowden C., Fieve R. et al. A double-blind placebo-controlledstudy of lamotrigine monotherapy in outpatients with bipolar I depression. J ClinPsychiatry.
1999;60:79-88.84. Calabrese J.R., Hirschfeld R.M., Reed M., Davies M.A., Frye M.A., KeckP.E., Lewis L., McElroy S.L., McNulty J.P., Wagner K.D.. Impact of bipolardisorder on a U.S. community sample. J Clin Psychiatry. 2003;64(4):425-432.85. Calabrese J.R., Keck P.E. Jr., McFadden W. A randomized, double-blind,placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.Am J Psychiatry. 2005;162:1351-1360.86. Calabrese J.R., McFadden W., McCoy R. et al. Double-blind placebo-controlledstudy of quetiapine in bipolar depression.
APA Annual Meeting, New York,Abstarcts NR 2004, vol. 284.87. Calabrese J.R., Shelton M.D., Bowden C.L. et al. Bipolar rapid cycling: Focus ondepression as its hallmark. J Clin Psychiatry. 2001;62(Suppl14):34-41.88. Cassano G.B., Akiskal H.S., Savino M. et al. Proposed subtypes of bipolar II andrelated disorders: With hypomanic episodes (or cyclothymia) and withhyperthymic temperament.
J Affect Disord. 1992;26:127-140.89. Compton M.T., Nemeroff C.B. The treatment of bipolar depression. J ClinPsychiatry. 2000;61(9):57-67.90. Corapcioglu A., Kocabasoglu N., Yargic I. A randomized, single-blind,multicenter prospective trial comparing the efficacy and safety of paroxetine with118and without quetiapine therapy in depression associated with anxiety.International Journal of Psychiatry in Clinical Practice. 2004;8(4):205-211.91. Coryell W. Bipolar II disorder: The importance of hypomania. Washington DC: American Psychiatric Publishing; 1999.92. Coryell W., Endicott J., Maser J.D., Keller M.B., Leon A.C., Akiskal H.S.
Longterm stability of polarity distinctions in the affective disorders. Am J Psychiatry.1995;152(3):385-390.93. Coryell W., Keller M., Endicott J. et al. Bipolar illness: course and outcome overa five-year period. Psychol Med. 1989;19:129-141.94. Coryell W., Scheftner W., Keller M. et al. The enduring psychosocialconsequences of mania and depression. Am J Psychiatry. 1993;150:720-727.95. Doree J.P., Tourjman V., Kunicki S., Desrosiers J., Vanise C., Elie R., Lew V.A.Comparison of quetiapine versus lithium treatment of resistant depression. АРАAnnual Meeting, New YORK, Abstracts NR 2004, 273.96. Dunner D., Patrick V., Fieve R. Rapid cycling manic-depressive patients.Comprehensive Psychiat. 1977;18(6):561-566.97.
Dunner D.L., Amsterdam J.D., Shelton R.C. et al. Adjunctive ziprasidone intreatment-resistant depression: a pilot study. APA annual meeting. – SanFrancisco, Abstracts, 2003, 89 p.98. Dunner D.L., Gershon E.S., Goodwin F.K. Heritable factors in the severity ofaffective illness. Biol Psychiatry. 1976;11:31-42.99. Endicott J., Nee J., Andersen N.
et al. Bipolar II: combine or keep separate? JAffect Disord. 1985;8:17-28.100. Fornaro M., McCarthy M.J., De Berardis D., De Pasquale C., Tabaton M.,Martino M., Colicchio S., Cattaneo C.I., D'Angelo E., Fornaro P. Adjunctiveagomelatine therapy in the treatment of acute bipolar II depression: a preliminaryopen label study. Neuropsychiatr Dis Treat. 2013;9:243-251.119101. Fountoulakis K.N., Vieta E., Sanchez-Moreno J., Kaprinis S.G., Goikolea J.M.,Kaprinis G.S. Treatment guidelines for bipolar disorder: A critical review.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
